Depression Treatment

Introduction to Depression Treatment

• Depression treatment typically involves the use of second-generation antidepressants, primarily SSRIs, as first-line treatment due to their better adverse effect profile compared to older antidepressants, as recommended by the American Academy of Family Physicians 1

Contraindications and Warnings

• The European Heart Journal recommends that atomoxetine should not be prescribed to a patient taking escitalopram 20 mg due to the increased risk of QT interval prolongation and potential for serotonin syndrome 2
• The combination of atomoxetine and escitalopram may amplify cardiovascular side effects, as both medications can independently cause these effects 2
• Escitalopram has been associated with QT interval prolongation, as reported by the European Heart Journal 2
• Pregnant patients should be aware of the risk of neonatal complications, and patients with hepatic or renal impairment require dose adjustments, especially for escitalopram, as recommended by clinical guidelines 3
• Elderly patients should start with lower doses due to increased risk of side effects, especially hyponatremia and falls, and should be closely monitored for adverse effects 3

Medication Selection and Dosing

• SSRIs are commonly used, but nausea is one of the most common reasons for discontinuation, is usually mild and temporary, according to the American College of Physicians 4
• Sexual dysfunction occurs in approximately 40% of patients on SSRIs, as reported by the American Academy of Family Physicians 1
• Bupropion has a decreased risk of sexual side effects compared to SSRIs and may be considered if sexual dysfunction becomes problematic, according to the American Academy of Family Physicians 1
• SNRIs (e.g., duloxetine) may be considered if the patient does not respond to or cannot tolerate SSRIs, with marginally superior remission rates (49% vs. 42%), as reported by the American Academy of Family Physicians 1
• Sertraline (Zoloft) is a consideration for female patients who may become pregnant, as it transfers in lower concentrations to breast milk and produces undetectable infant plasma levels, as noted by the American Academy of Family Physicians 1
• The initial dose for children and adolescents (8 years and older) is 10-20 mg/day, which may be increased to 20 mg/day after several weeks if needed, according to the FDA 5
• Lower starting doses (approximately 50% of the adult dose) are recommended for certain populations, such as older adults, due to fluoxetine's long half-life and side effect profile, with preferred alternatives including citalopram, escitalopram, bupropion, mirtazapine, venlafaxine, and sertraline, as suggested by the American Academy of Family Physicians 1
• The recommended dosing for SSRIs in adolescents is as follows:

6, 7, 8

Monitoring and Side Effects

• Close monitoring is necessary for suicidal thinking and behavior, as well as behavioral activation/agitation, in adolescents up to 24 years old, especially during the first months of treatment, as recommended by the American Academy of Child and Adolescent Psychiatry 3
• Regular monitoring is recommended for side effects, including gastrointestinal effects, neurological effects, sleep disturbances, and sexual dysfunction, with strategies to manage side effects including dose reduction, drug holiday, and switching to medications with fewer side effects 3, 4, 1, 9, 10
• There is a slightly increased risk of suicidal ideation and behavior in adults 18-24 years of age (OR = 2.30; 95% CI, 1.04 to 5.09), as noted by the American Academy of Family Physicians 1
• Be aware of the risk of serotonin syndrome when combining SSRIs with other serotonergic medications, as advised by the American Psychiatric Association 6

Augmentation and Alternative Therapies

• Aripiprazole is an effective augmentation agent for patients with SSRI-resistant symptoms, with evidence supporting its use, and can be considered as an adjunctive therapy 11
• Buspirone can be used as an augmentation agent, with a starting dose of 5 mg twice daily and a maximum dose of 20 mg three times daily, and can be considered for patients who do not respond to initial treatment 7
• Mirtazapine is an alternative option for adjunctive therapy, with anxiolytic properties, and can improve sleep and cognitive function, starting at 7.5-15mg at bedtime, and can be increased to 30-45mg, as recommended by clinical guidelines 6
• CBT has comparable efficacy to second-generation antidepressants, such as paroxetine, with fewer adverse effects 9

Treatment Duration and Efficacy

• Treatment should continue for at least 1-2 years, and efficacy should not be evaluated before 8 weeks of treatment, with longer treatment recommended for recurrent depression, as advised by medical professionals 1
• The American College of Physicians suggests assessing for clinical improvement using standardized measures, such as symptom rating scales, to determine efficacy of paroxetine treatment 9